About Archaemetzincin-2
Archaemetzincin-2 (AMZ2) is a protein
from Homo sapiens identified by UniProt accession
Q86W34, 360 residues long.
MolForge cross-references it against 0 known binders and
16 disease associations.
Target properties
| Protein name | Archaemetzincin-2 |
|---|
| UniProt accession | Q86W34 |
|---|
| Gene | AMZ2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 360 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (16)
Diseases linked to this target (Open Targets).
- loneliness measurement · score 0.29
- neurodegenerative disease · score 0.29
- electrocardiography · score 0.22
- type 1 diabetes mellitus · score 0.21
- monoclonal B-cell lymphocytosis · score 0.11
- sodium measurement · score 0.04
- chloride measurement · score 0.04
- bilirubin measurement · score 0.03
- high density lipoprotein cholesterol measurement · score 0.03
- glucuronate measurement · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86W34-F1 | alphafold | PREDICTED | 90.22 | — |
Amino-acid sequence (360 residues)
MQIIRHSEQT LKTALISKNP VLVSQYEKLN AGEQRLMNEA FQPASDLFGP ITLHSPSDWI TSHPEAPQDF EQFFSDPYRK TPSPNKRSIY IQSIGSLGNT RIISEEYIKW LTGYCKAYFY GLRVKLLEPV PVSVTRCSFR VNENTHNLQI HAGDILKFLK KKKPEDAFCV VGITMIDLYP RDSWNFVFGQ ASLTDGVGIF SFARYGSDFY SMHYKGKVKK LKKTSSSDYS IFDNYYIPEI TSVLLLRSCK TLTHEIGHIF GLRHCQWLAC LMQGSNHLEE ADRRPLNLCP ICLHKLQCAV GFSIVERYKA LVRWIDDESS DTPGATPEHS HEDNGNLPKP VEAFKEWKEW IIKCLAVLQK
Explore Archaemetzincin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets